240 related articles for article (PubMed ID: 21557637)
1. Immune therapy for ovarian cancer: promise and pitfalls.
Thibodeaux SR; Curiel TJ
Int Rev Immunol; 2011; 30(2-3):102-19. PubMed ID: 21557637
[TBL] [Abstract][Full Text] [Related]
2. Current approaches in ovarian cancer vaccines.
Reinartz S; Wagner U
Minerva Ginecol; 2004 Dec; 56(6):515-27. PubMed ID: 15729204
[TBL] [Abstract][Full Text] [Related]
3. Vaccine-based clinical trials in ovarian cancer.
Leffers N; Daemen T; Boezen HM; Melief KJ; Nijman HW
Expert Rev Vaccines; 2011 Jun; 10(6):775-84. PubMed ID: 21692699
[TBL] [Abstract][Full Text] [Related]
4. Harnessing the immune system for ovarian cancer therapy.
Odunsi K; Sabbatini P
Am J Reprod Immunol; 2008 Jan; 59(1):62-74. PubMed ID: 18154597
[TBL] [Abstract][Full Text] [Related]
5. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
[TBL] [Abstract][Full Text] [Related]
6. Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer.
Cannon MJ; O'Brien TJ; Underwood LJ; Crew MD; Bondurant KL; Santin AD
Expert Rev Anticancer Ther; 2002 Feb; 2(1):97-105. PubMed ID: 12113075
[TBL] [Abstract][Full Text] [Related]
7. Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer.
Santin AD; Bellone S; Underwood LJ; O'Brien TJ; Ravaggi A; Pecorelli S; Cannon MJ
Minerva Ginecol; 2002 Apr; 54(2):133-44. PubMed ID: 12032451
[TBL] [Abstract][Full Text] [Related]
8. Immunologic approaches to ovarian cancer treatment.
Sabbatini P; Odunsi K
J Clin Oncol; 2007 Jul; 25(20):2884-93. PubMed ID: 17617519
[TBL] [Abstract][Full Text] [Related]
9. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.
Moschella F; Proietti E; Capone I; Belardelli F
Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of metastasis.
Dallal RM; Lotze MT
Surg Oncol Clin N Am; 2001 Apr; 10(2):433-47, xi. PubMed ID: 11382596
[TBL] [Abstract][Full Text] [Related]
11. The unfulfilled promise of melanoma vaccines.
Livingston P
Clin Cancer Res; 2001 Jul; 7(7):1837-8. PubMed ID: 11448892
[No Abstract] [Full Text] [Related]
12. Vaccination as a treatment for breast or ovarian cancer.
Holmberg LA; Sandmaier B
Expert Rev Vaccines; 2004 Jun; 3(3):269-77. PubMed ID: 15176943
[TBL] [Abstract][Full Text] [Related]
13. Biological therapy of ovarian cancer: current directions.
Bookman MA
Semin Oncol; 1998 Jun; 25(3):381-96. PubMed ID: 9633851
[TBL] [Abstract][Full Text] [Related]
14. Current developments with peptide-based human tumor vaccines.
Khazaie K; Bonertz A; Beckhove P
Curr Opin Oncol; 2009 Nov; 21(6):524-30. PubMed ID: 19770763
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapeutics in development for prostate cancer.
Harzstark AL; Small EJ
Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
[TBL] [Abstract][Full Text] [Related]
16. Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment?
Chiriva-Internati M; Cobos E; Cannon MJ
Int Rev Immunol; 2011; 30(2-3):67-70. PubMed ID: 21557634
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy opportunities in ovarian cancer.
Chu CS; Kim SH; June CH; Coukos G
Expert Rev Anticancer Ther; 2008 Feb; 8(2):243-57. PubMed ID: 18279065
[TBL] [Abstract][Full Text] [Related]
18. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
19. Antitumor vaccination: where we stand.
Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
[TBL] [Abstract][Full Text] [Related]
20. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer.
Adams M; Navabi H; Croston D; Coleman S; Tabi Z; Clayton A; Jasani B; Mason MD
Vaccine; 2005 Mar; 23(17-18):2374-8. PubMed ID: 15755631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
